Aerie Pharmaceuticals Stock Buy or Sell? AERI Stocks Forecast

Market Capitalization: N/A $
Price to Earnings: N/A
Quarterly Earnings Growth YOY: N/A
Quarterly Revenue Growth YOY: N/A
Trailing PE: N/A
Forward PE: N/A
Shares Outstanding: N/A

Aerie Pharmaceuticals Stock Buy or Sell? AERI Stocks Analytic Forecasts

April 1, 2023 (04:28)

Aerie Pharmaceuticals, Inc. (AERI) Sector: Healthcare

We present you the most up-to-date and complete review of analytical trend forecasts and views on the AERI stock market. Experts share their opinions on what to expect from the Aerie Pharmaceuticals, Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Aerie Pharmaceuticals stocks.

Aerie Pharmaceuticals, Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy AERI Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Andy Jones and is titled

“Aerie Looks Modestly Undervalued Despite High Cash Burn”

is published on June 6 (2020) and has 3 likes. The review predicts Bullish market trend.

It summarize the following theses:

  • Aerie has 2 marketed products and decent pipeline after a recent acquisition.
  • Aerie unfortunately still has extremely high cash burn for a company of its size.
  • Despite this, Aerie shares appear to be somewhat undervalued at present even after accounting for the almost certain dilution that will be needed to raise cash.

The author starts his analytic review with the following:

Aerie’s 2 Marketed Products Should Start to Show Substantially Increasing Sales in the Coming Years Aerie has 2 marketed products, Rhopressa and Rocklatan. Rhopressa was first to hit the market, launching in April 2018. Rhopressa is a once-daily eye drop for the treatment of open angle glaucoma. Rhopressa is a Rho kinase inhibitor which works to lower intraocular pressure by directly impacting outflow through the trabecular meshwork, rather than targeting aqueous humor outflow like the prior standard of care class of drugs, prostaglandins. Rhopressa’s launch represents the first new class of drugs approved to treat glaucoma in years. Rhopressa appears to have a better safety profile and more universal efficacy versus prostaglandins as well as reducing the required number of daily drops for 2 to just 1.

Andy Jones has already 1967 followers,
which shows, he is the one who cares for his words. Andy Jones has 92 works published.
The contributor of experts community since 2020

One more noteworthy article is written by Bret Jensen under the title

“Reassessing Aerie Pharmaceuticals”

on October 10 (2019) and has 2 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add AERI stocks to your investment portfolio or not, and helps to work out your own Aerie Pharmaceuticals stock selling strategies:

  • Today, we revisit ocular concern Aerie Pharmaceuticals.
  • The company has struggled as a newly minted ‘Tier 3’, with the stock down some 60% in 2019 to date.
  • A fully updated investment analysis is presented in the paragraphs below.

Bret Jensen starts analysis with such words:

Today, we revisit an ocular concern that was a big winner a few years ago as it advanced its product portfolio. However, commercialization has been a different story, and the stock has had a sharp drop in 2019. We revisit this small-cap name in the paragraphs below.

This author is very popular among the auditory. He has 45831 followers

Bret Jensen is the contributor of experts community since 2010. Has published at least 3948 articles.

Another analysis presented by SA PRO Short Ideas came out on July 15 (2019). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for AERI stocks. It sounds like

“Aerie Pharmaceuticals: Guidance Is Unachievable After Failed Drug Launches; 70%+ Downside”

Article has got 2 likes at the moment and forecasting trend of the market.

Summarizing the information presented in the review concerning the Aerie Pharmaceuticals, Inc., the expert says the following:

  • Sell-side estimates for this quarter’s revenue are too high and have begun to be cut.
  • The guidance of 110m in revenue for the year is very unlikely to be achieved, which will result in even higher than expected cash burn.
  • Sales of Rocklatan and Rhopressa to pharmacies and distributors exceed prescriptions, creating a demand headwind for the future.
  • Strategic acquirers are unlikely to be interested in buying AERI in the near future.

And here, what comes first:

I’ll begin with an analysis this quarter’s sales of Rhopressa and Rocklatan using weekly prescription data from Bloomberg / Symphony Health. The dates do not perfectly line up with quarter ends, but the difference is minimal and the monthly data for June is not available yet.

SA PRO Short Ideas has already 1015 followers, which shows, he is the one who cares for his words.
The contributor of experts community since 2019. Has already 206 analytic reviews published.

The Share Price of Aerie Pharmaceuticals, Inc. (AERI) for now

What analysts predict: $
52-week high/low: $ / $

50/200 Day Moving Average: $ / $

The average stock price over the previous 50/200 days. For Aerie Pharmaceuticals stocks, the 50-day moving average is the support level for now. For AERI stocks, the 200-day moving average is the support level today.

See the Detailed Predictions for AERI stock with charts and tables

Related Analysis

View all analytics

Buy or Sell ADGI shares?
January 1, 1970

Tilray: Down 89%, But Still Far From A Bargain

Buy or Sell TLRY shares? Tilray: Down 89%, But Still Far From A Bargain
March 20, 2023
Cannabis stocks remain highly exposed to the Canadian market; Tilray, long Canada's top producer, is especially so.

UnitedHealth Group: May Seem Overvalued But Significant Upside Still Ahead

Buy or Sell UNH shares? UnitedHealth Group: May Seem Overvalued But Significant Upside Still Ahead
March 29, 2023
Despite trading at higher valuation multiples than its peers, the stock's fair value is between $529 and $720 per share, which is a 10% to 50% upside from current levels.

OPKO Health And Merck Shares: Buy Or Sell After Epstein Barr Vaccine Deal?

Buy or Sell MRK shares? OPKO Health And Merck Shares: Buy Or Sell After Epstein Barr Vaccine Deal?
March 23, 2023
This month Florida-based OPKO Health announced it had entered into an agreement with pharma giant Merck to develop a vaccine for Epstein Barr Virus.